» Articles » PMID: 37355631

The New Insights into Autophagy in Thyroid Cancer Progression

Overview
Journal J Transl Med
Publisher Biomed Central
Date 2023 Jun 24
PMID 37355631
Authors
Affiliations
Soon will be listed here.
Abstract

In recent decades, the incidence of thyroid cancer keeps growing at a shocking rate, which has aroused increasing concerns worldwide. Autophagy is a fundamental and ubiquitous biological event conserved in mammals including humans. Basically, autophagy is a catabolic process that cellular components including small molecules and damaged organelles are degraded for recycle to meet the energy needs, especially under the extreme conditions. The dysregulated autophagy has indicated to be involved in thyroid cancer progression. The enhancement of autophagy can lead to autophagic cell death during the degradation while the produced energies can be utilized by the rest of the cancerous tissue, thus this influence could be bidirectional, which plays either a tumor-suppressive or oncogenic role. Accordingly, autophagy can be suppressed by therapeutic agents and is thus regarded as a drug target for thyroid cancer treatments. In the present review, a brief description of autophagy and roles of autophagy in tumor context are given. We have addressed summary of the mechanisms and functions of autophagy in thyroid cancer. Some potential autophagy-targeted treatments are also summarized. The aim of the review is linking autophagy to thyroid cancer, so as to develop novel approaches to better control cancer progression.

Citing Articles

Relationship between programmed cell death and targeted therapy for thyroid cancer in patients with a poor prognosis: an update.

Zhao Y, Zhao S, Fan Z, Zhao Y, Wang G Discov Oncol. 2025; 16(1):112.

PMID: 39899135 PMC: 11790539. DOI: 10.1007/s12672-025-01815-w.


The Fundamental Role of Oxime and Oxime Ether Moieties in Improving the Physicochemical and Anticancer Properties of Structurally Diverse Scaffolds.

Fotie J, Matherne C, Mather J, Wroblewski J, Johnson K, Boudreaux L Int J Mol Sci. 2023; 24(23).

PMID: 38069175 PMC: 10705934. DOI: 10.3390/ijms242316854.


Anaplastic thyroid cancer cells reduce CD71 levels to increase iron overload tolerance.

DAprile S, Denaro S, Pavone A, Giallongo S, Giallongo C, Distefano A J Transl Med. 2023; 21(1):780.

PMID: 37924062 PMC: 10625232. DOI: 10.1186/s12967-023-04664-9.


The potential role of reprogrammed glucose metabolism: an emerging actionable codependent target in thyroid cancer.

Duan S, Wu M, Zhang Z, Chang S J Transl Med. 2023; 21(1):735.

PMID: 37853445 PMC: 10585934. DOI: 10.1186/s12967-023-04617-2.

References
1.
Levine B, Kroemer G . Autophagy in the pathogenesis of disease. Cell. 2008; 132(1):27-42. PMC: 2696814. DOI: 10.1016/j.cell.2007.12.018. View

2.
Mowers E, Sharifi M, Macleod K . Autophagy in cancer metastasis. Oncogene. 2016; 36(12):1619-1630. PMC: 5337449. DOI: 10.1038/onc.2016.333. View

3.
Kunanopparat A, Kimkong I, Palaga T, Tangkijvanich P, Sirichindakul B, Hirankarn N . Increased ATG5-ATG12 in hepatitis B virus-associated hepatocellular carcinoma and their role in apoptosis. World J Gastroenterol. 2016; 22(37):8361-8374. PMC: 5055866. DOI: 10.3748/wjg.v22.i37.8361. View

4.
Mathew R, Karp C, Beaudoin B, Vuong N, Chen G, Chen H . Autophagy suppresses tumorigenesis through elimination of p62. Cell. 2009; 137(6):1062-75. PMC: 2802318. DOI: 10.1016/j.cell.2009.03.048. View

5.
Plews R, Yusof A, Wang C, Saji M, Zhang X, Chen C . A novel dual AMPK activator/mTOR inhibitor inhibits thyroid cancer cell growth. J Clin Endocrinol Metab. 2015; 100(5):E748-56. PMC: 4422890. DOI: 10.1210/jc.2014-1777. View